These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3666587)

  • 1. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production.
    Cattaneo M; Bevilacqua C; Lecchi A; Mannucci PM
    Haemostasis; 1987; 17(5):293-300. PubMed ID: 3666587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of aspirin and indobufen in healthy volunteers.
    Lee JY; Sung KC; Choi HI
    Platelets; 2016; 27(2):105-9. PubMed ID: 26083594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific inhibition of 40 K protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen.
    Mamiya S; Hagiwara M; Ishikawa T; Hidaka H
    Thromb Res; 1989 Jun; 54(5):447-56. PubMed ID: 2505401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production.
    Cattaneo M; Tenconi PM; Lecchi A; Mannucci PM
    Thromb Res; 1991 Jun; 62(6):717-24. PubMed ID: 1926062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane production by platelets during tumor cell-induced platelet activation.
    Pacchiarini L; Zucchella M; Milanesi G; Tacconi F; Bonomi E; Canevari A; Grignani G
    Invasion Metastasis; 1991; 11(2):102-9. PubMed ID: 1917383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (+/-)-indobufen.
    Cerletti C; Manarini S; Colombo M; Tavani A
    J Pharm Pharmacol; 1990 Dec; 42(12):885-7. PubMed ID: 1983157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
    Yang M; Ye Z; Mei L; Ullah I; Tan C; Wang G; Gu Q; Lu Y; Abdus S; Shi L; Gong X; Bai J; Eikelboom JW; Li C
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1815-1823. PubMed ID: 34331551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsaturated platelet-activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes.
    Korth R; Riess H; Brehm G; Hiller E
    Thromb Res; 1986 Mar; 41(5):699-706. PubMed ID: 3961742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man.
    De Caterina R; Sicari R; Yan A; Bernini W; Giannessi D; Lazzerini G; Efthymiopoulos C; Strolin-Benedetti M
    Thromb Haemost; 1992 Feb; 67(2):258-63. PubMed ID: 1621247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of indobufen on platelet thromboxane B2 production in patients with myocardial infarction.
    Rebuzzi AG; Natale A; Bianchi C; Mariello F; Coppola E; Ciabattoni G
    Eur J Clin Pharmacol; 1990; 39(1):99-100. PubMed ID: 2276396
    [No Abstract]   [Full Text] [Related]  

  • 12. The inhibitory effect of 2-thienyl 2'-hydroxyphenyl ketone (C85) on platelet thromboxane formation.
    Chou TC; Hsu LY; Yen MH; Ding YA
    Thromb Res; 1996 Oct; 84(2):83-95. PubMed ID: 8897698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of phentolamine on platelet aggregation, thromboxane B2 production and release reaction.
    Anfossi G; Trovati M; Mularoni E; Lanzio M; Massucco P; Emanuelli G
    Arch Int Pharmacodyn Ther; 1988; 296():144-54. PubMed ID: 2853612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.
    Davì G; Patrono C; Catalano I; Custro N; Giammarresi C; Ganci A; Cosentino F; Notarbartolo A
    Arterioscler Thromb; 1993 Sep; 13(9):1346-9. PubMed ID: 8364018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood.
    Patrignani P; Volpi D; Ferrario R; Romanzini L; Di Somma M; Patrono C
    Eur J Pharmacol; 1990 Nov; 191(1):83-8. PubMed ID: 1965501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.
    Vinazzer H; Fuccella LM
    J Clin Pharmacol; 1980; 20(5-6 Pt 1):316-25. PubMed ID: 7400367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in thromboxane production between neonatal and adult platelets in response to arachidonic acid and epinephrine.
    Stuart MJ; Dusse J; Clark DA; Walenga RW
    Pediatr Res; 1984 Sep; 18(9):823-6. PubMed ID: 6435080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
    Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
    Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of platelet aggregation by areca nut and betel leaf ingredients: roles of reactive oxygen species and cyclooxygenase.
    Jeng JH; Chen SY; Liao CH; Tung YY; Lin BR; Hahn LJ; Chang MC
    Free Radic Biol Med; 2002 May; 32(9):860-71. PubMed ID: 11978487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of trifluoperazine on platelet activation.
    Ardlie NG; Boatwright C; Garrett J; McGuiness JA
    Thromb Res; 1985 Jun; 38(6):695-706. PubMed ID: 3161211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.